The study found that dapagliflozin reduced the risk of heart failure hospitalization by about 80% in patients carrying cardiomyopathy-associated genetic variants, compared with placebo. The post Diabetes Drug Linked to Reduced Heart Failure in High-Risk Gene Carriers appeared first on Inside Precision Medicine .